[Comparative transcriptome pairwise analysis of spontaneously transformed multipotent stromal cells from human adipose tissue].
Omel'chenko DO., Rzhaninova AA., Gol'dshteĭn DV.
Laboratory Study, published in Genetika (2014) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Genetika (2014)
- Country
- Russia (Federation)
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 25711018
Abstract (original English)
Potential markers and the mechanism of the spontaneous transformation of multipotent stromal cells (MSC) with perivascular immunophenotype have been determined. A transcriptome comparative study was performed involving six paired specimens of normal and spontaneously transformed MSC with perivascular immunophenotype, obtained in the first passages following the isolation of adipose tissue of six healthy donors. According to the results obtained using the microarray Illumina HT-12 v4 with the Significance Analysis of Microarrays software, differentially expressed transcripts were revealed and a statistical analysis using Gene Ontology and Molecular Signatures Databases was conducted. The association of the spontaneous transformation of isolated MSC with perivascular immunophenotype with previously identified oncogenic cell transformation pathways (E2F, ATR/ATM, RAS, and RHOA) is suggested and further aims for more detailed study are set. Potential transformation markers, including largely unknown genes and those previously not associated with cancer genes (HSPB6, PLAC9, FEZ1, DTWD1, APH1A, and ATP5L) are described.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.